MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval

A key health ministry advisory committee on November 25 gave its thumbs-up for an array of new medicines for approval, including Bayer Yakuhin’s prostate cancer drug darolutamide and AbbVie’s oral selective JAK inhibitor upadacitinib for the treatment of rheumatoid arthritis...read more